Three recent graduates from the MSU photo program noticed a glaring gap in the photo-journal world. While there has been ...

AI companies such as OpenAI and Anthropic have long focused on building tools that can write code that will speed up software ...

Biopharma may see a happier year ahead in 2026 than in recent years, according to analysts at William Blair. For one thing, the industry’s top stocks have recovered from lows that stretched into last ...

C compiler, LustreC, into a generator of both executable code and associated specification. Model-based design tools are ...

Former Google CEO Eric Schmidt expressed shock at artificial intelligence's rapid advancement in software development, declaring his own obsolescence after witnessing an AI system generate an entire ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

A new research paper reframes the simulation hypothesis, asking whether reality could be simulated and what science can test.

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...